<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251771</url>
  </required_header>
  <id_info>
    <org_study_id>1.2005.650</org_study_id>
    <secondary_id>EUDRACT No.2005-004486-42</secondary_id>
    <nct_id>NCT00251771</nct_id>
  </id_info>
  <brief_title>Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis</brief_title>
  <acronym>CaVenT</acronym>
  <official_title>Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Ostfold, Fredrikstad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular
      weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e.
      post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been
      introduced worldwide the last two decades. Reports have suggested a beneficial effect of this
      costly treatment, but there are no randomized clinical trials documenting its short- and
      long-term efficacy and safety. This multi-center study will randomize patients with acute
      iliofemoral vein thrombosis to either conventional treatment or CDT in addition to
      conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence
      of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will
      increase patency of the affected segments after 6 months from &lt;50% to &gt;80%. The main
      long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS
      after 2 years from &gt;25% to &lt;10%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency after 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-thrombotic syndrome after 2 years (yrs)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinically relevant bleeding complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on quality of life</measure>
    <time_frame>2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success of CDT</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency at 2 years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTS at 6, 12, 36, 48 and 60 months</measure>
    <time_frame>6, 12, 36, 48 and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation between PTS and patency</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of vein anomalies</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of underlying thrombophilia</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of recurrent venous thrombotic events (VTE)</measure>
    <time_frame>0.5, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of importance for recurrent thrombosis</measure>
    <time_frame>0.5, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of importance for successful thrombolysis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>catheter-directed venous thrombolysis</intervention_name>
    <description>catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of symptoms &lt;21 days

          -  Objectively verified DVT of the femoral or common iliac veins or the combined
             iliofemoral segment

          -  Informed consent

        Exclusion Criteria:

          -  Anticoagulant therapy prior to trial entry &gt;7 days

          -  Contraindications to thrombolytic therapy

          -  Indications for thrombolytic therapy, i.e. phlegmasia coerulea dolens or vena cava
             thrombosis

          -  Severe anemia, hemoglobin (hgb)&lt;8 g/dl

          -  Thrombocytopenia, platelets &lt;80x10^9/l

          -  Severe renal failure, creatinine clearance &lt;30ml/min

          -  Severe hypertension, systolic (syst) blood pressure (BP)&gt;160 mmHg or diastolic (diast)
             BP &gt;100 mmHg pregnancy

          -  Less than 14 days post-surgery or post-trauma

          -  History of subarachnoidal or intracerebral bleeding

          -  Disease with life expectancy &lt;24 months

          -  Drug abuse or mental disease that may interfere with treatment and follow-up

          -  Former ipsilateral proximal DVT

          -  Chemotherapy or advanced malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Morten Sandset, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.thelancet.com/journals/lancet/misc/protocol/07PRT-295</url>
    <description>Protocol Reviews in the Lancet.com</description>
  </link>
  <reference>
    <citation>Enden T, Kløw NE, Sandset PM. [Catheter-directed thrombolysis in acute deep venous thrombosis]. Tidsskr Nor Laegeforen. 2006 Jun 22;126(13):1765. Norwegian.</citation>
    <PMID>16794675</PMID>
  </reference>
  <reference>
    <citation>Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen LO, Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM. Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). Am Heart J. 2007 Nov;154(5):808-14. Epub 2007 Sep 6.</citation>
    <PMID>17967583</PMID>
  </reference>
  <reference>
    <citation>Enden T, Garratt AM, Kløw NE, Sandset PM. Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire. Scand J Caring Sci. 2009 Jun;23(2):369-74. doi: 10.1111/j.1471-6712.2008.00618.x. Epub 2008 Nov 12.</citation>
    <PMID>19068041</PMID>
  </reference>
  <reference>
    <citation>Enden T, Sandset PM, Kløw NE. Evidence-based practice for patients with severe venous thrombosis. Tidsskr Nor Laegeforen. 2012 May 29;132(10):1215-6. doi: 10.4045/tidsskr.12.0474. English, Norwegian.</citation>
    <PMID>22669381</PMID>
  </reference>
  <results_reference>
    <citation>Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009 Aug;7(8):1268-75. doi: 10.1111/j.1538-7836.2009.03464.x. Epub 2009 Apr 30.</citation>
    <PMID>19422443</PMID>
  </results_reference>
  <results_reference>
    <citation>Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012 Jan 7;379(9810):31-8. doi: 10.1016/S0140-6736(11)61753-4. Epub 2011 Dec 13.</citation>
    <PMID>22172244</PMID>
  </results_reference>
  <results_reference>
    <citation>Haig Y, Enden T, Slagsvold CE, Sandvik L, Sandset PM, Kløw NE. Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis. J Vasc Interv Radiol. 2013 Jan;24(1):17-24; quiz 26. doi: 10.1016/j.jvir.2012.09.023. Epub 2012 Nov 22.</citation>
    <PMID>23176966</PMID>
  </results_reference>
  <results_reference>
    <citation>Enden T, Resch S, White C, Wik HS, Kløw NE, Sandset PM. Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. J Thromb Haemost. 2013 Jun;11(6):1032-42. doi: 10.1111/jth.12184.</citation>
    <PMID>23452204</PMID>
  </results_reference>
  <results_reference>
    <citation>Enden T, Wik HS, Kvam AK, Haig Y, Kløw NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open. 2013 Aug 29;3(8):e002984. doi: 10.1136/bmjopen-2013-002984.</citation>
    <PMID>23988361</PMID>
  </results_reference>
  <results_reference>
    <citation>Enden T, Kløw NE, Sandset PM. Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis. Patient Relat Outcome Meas. 2013 Sep 16;4:55-9. doi: 10.2147/PROM.S47233. eCollection 2013.</citation>
    <PMID>24082798</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombolytic therapy</keyword>
  <keyword>Postphlebitic syndrome</keyword>
  <keyword>Venous thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

